NEW YORK (360Dx) – iBio said today it and Oneway Diagnostica of Brazil have reached a deal to develop point-of-care diagnostic tests for Brazil with an initial focus on Zika and chikungunya.

As part of the deal, iBio will provide antigen and antibody manufacturing for product prototype development, regulatory approval, commercial launch, and ongoing commercialization efforts, while Oneway will manage marketing, distribution, and sales in Brazil.  

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.